Inozyme Pharma Inc — Company Overview, News & Financial Data
Inozyme Pharma is a biopharmaceutical company focused on therapies for rare diseases of mineralization.
Inozyme Pharma Inc
Company profile
About Inozyme Pharma Inc
Inozyme Pharma (NASDAQ:INZY) is a biopharmaceutical company dedicated to developing therapies that treat the unmet medical needs of patients with rare diseases of mineralization. Specializing in the research and development stage, the company primarily focuses on advancing innovative treatments for diseases such as ENPP1 Deficiency and ABCC6 Deficiency which affect the body's ability to properly mineralize bone and soft tissues. At the heart of Inozyme Pharma's objectives lies a commitment to improving the quality of life for patients suffering from these debilitating conditions. Through a blend of cutting-edge science and collaboration with communities, healthcare professionals, and researchers, Inozyme Pharma aims to bring breakthrough therapies from the lab to the clinic.
Snapshot
2015Year founded
59Employees
Boston, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
Boston, US
Products and/or services of Inozyme Pharma Inc
- Development of INZ-701, aimed at treating ENPP1 Deficiency, a rare, genetic condition leading to arterial and bone abnormalities.
- Advancement of therapies for ABCC6 Deficiency, focusing on pseudoxanthoma elasticum (PXE), improving mineralization.
- Research on potential treatments for Generalized Arterial Calcification of Infancy (GACI), caused by ENPP1 or ABCC6 deficiencies.
- Exploration of uses of INZ-701 in treating calcification disorders beyond GACI and PXE, targeting broader patient populations.
- Investigation into novel pathways and targets for addressing rare mineralization disorders, expanding therapeutic options.
- Support services for patients and families dealing with rare genetic mineralization diseases, including educational and advocacy efforts.
Inozyme Pharma Inc executive team
- Dr. Douglas A. Treco Ph.D.CEO & Chairman
- Mr. Axel Bolte M.B.A., M.Sc.Co-Founder, Senior Advisor & Director
- Mr. Sanjay S. Subramanian M.B.A., M.S.CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary
- Dr. Matthew Winton Ph.D.Senior VP & COO
- Dr. Demetrios Braddock M.D., Ph.D.Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
- Dr. Yves Sabbagh Ph.D.Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board
- Mr. Stefan RileyDirector of Investor Relations
- Ms. Gayle GirondaSenior VP & Chief People Officer
- Mr. Stephen J. Di Palma M.B.A.Consultant
- Dr. Petra Duda M.D., Ph.D.Chief Medical Officer
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift